ArticleBMC women's health2026
Swede Score can predict high-grade cervical intraepithelial neoplasia without previous cytology in colposcopies with transformation zone types 1 or 2.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the Swede score for the prediction of high-grade cervical lesions in women undergoing colposcopy without cytology results. This simulates the upcoming scenario in Brazil of HPV-based screening for women testing positive for HPV 16/18.
methodsThis was a partial analysis of an ongoing cross-sectional study that prospectively included 86 women referred for colposcopy due to cytological abnormalities to a public referral center in Rio de Janeiro, Brazil, between September 2023 and June 2025. All women went to colposcopy evaluation. Colposcopy was performed by an examiner blinded to the referral cytology. For this analysis, we included all women with a fully visible squamocolumnar junction (transformation zone types 1 or 2). The gold standard was the histopathological report. In cases where no biopsy or excisional treatment was performed, classification relied on final colposcopic impression and cytology. Diagnostic performance (sensitivity, specificity, predictive values, and likelihood ratios) was calculated using different Swede score cutoffs. Post-test probabilities were calculated assuming a 20% pre-test probability of CIN2+.
resultsPrevalence of CIN2 + was 33.7%. Swede score ≥ 8 predicted CIN2 + with a positive predictive value (PPV) of 100% and a likelihood ratio of 55.17. Post-test probability in a HPV 16/18-positive scenario without cytology in this threshold was estimated at 93%.
conclusionThe Swede score cutoff ≥ 8 in women who tested positive for HPV 16/18 and had fully visible transformation zones can be an accurate method to predict that they have CIN2+. These results could support the decision to proceed with immediate treatment without prior cytology or biopsy.
trial registrationNot applicable. This study does not report the results of a health care intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.